Previously, receptor tyrosine kinase genomic alterations were detected in 20.6% of cases, affecting ERBB2, FGFR2, and MET, suggesting potential benefit from targeted therapy including MET-amplified gastric tumors and ERBB2 base substitutions [32]. Here, NTRK1 is linked to gastric neoplasm.